Compare WNEB & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WNEB | EOLS |
|---|---|---|
| Founded | 1853 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.8M | 284.3M |
| IPO Year | 2001 | 2018 |
| Metric | WNEB | EOLS |
|---|---|---|
| Price | $13.77 | $4.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $12.50 | ★ $15.50 |
| AVG Volume (30 Days) | 58.8K | ★ 794.8K |
| Earning Date | 04-22-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | ★ 33.93 | 1.23 |
| EPS | ★ 0.75 | N/A |
| Revenue | $44,000.00 | ★ $297,176,000.00 |
| Revenue This Year | N/A | $13.27 |
| Revenue Next Year | $5.61 | $17.62 |
| P/E Ratio | $18.52 | ★ N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $8.41 | $3.86 |
| 52 Week High | $14.52 | $12.28 |
| Indicator | WNEB | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 64.99 | 55.05 |
| Support Level | $12.07 | $4.10 |
| Resistance Level | $13.95 | $4.99 |
| Average True Range (ATR) | 0.27 | 0.21 |
| MACD | 0.11 | 0.06 |
| Stochastic Oscillator | 81.78 | 98.70 |
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.